Patents Issued in November 6, 2018
  • Patent number: 10117829
    Abstract: The subject invention provides improved diclofenac gel formulations.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 6, 2018
    Assignee: Ferring B.V.
    Inventors: Arnaud Grenier, Dario N. Carrara
  • Patent number: 10117830
    Abstract: A stable pharmaceutical composition that includes an active agent selected from 1-deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and a buffer, wherein the stable pharmaceutical composition is capable of being parenterally administered to a human without deleterious health effects. Pompe disease is an example of a lysosomal storage disorder. Pompe disease is caused by a deficiency in the enzyme acid alpha-glucosidase (GAA). GAA metabolizes glycogen, a storage form of sugar used for energy, into glucose.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 6, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hing Char, Sergey Tesler, Jiping Yang, Enrique Dilone
  • Patent number: 10117831
    Abstract: A product and process of manufacturing an edible soft-chewable dosage form for the delivery of pharmaceutically active ingredients or nutritional agents orally to an animal or human subject, by forming a granulated soft-chew mass by appropriate mixing and sifting steps, and forming tablets with a compression press. Such soft-chew dosage forms have hardness of less than about 2 kilopond and friability of less than about 1% at 300 rotations (per USP). The process for manufacturing such compressed soft-chew tablets employs compression (tablet) pressing equipment to produce soft-chew tablets of consistent weight and texture.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: November 6, 2018
    Assignee: First Time US Generics LLC
    Inventors: Manesh A. Dixit, Vaibhav L. Pawar, Rushi R. Patel, Mineshkumar D. Patel, Amol Somwanshi
  • Patent number: 10117832
    Abstract: Provided herein are methods and processes for emulsifying non-polar compounds, such as omega fatty acids. Also provided are compositions that can be prepared according to the methods and processes described herein. The compositions, for example, have a high amount of the non-polar compound, such as a large amount of omega fatty acids. The non-polar compounds are also present in very small droplets within composition. For example, the mean or median particle size of the droplets is less than about 5 ?m. Further, the composition includes a low amount of surfactant, such as less than about 10-15% of the surfactant.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 6, 2018
    Assignee: BARLEAN'S ORGANIC OILS, LLC
    Inventor: Peter Nguyen
  • Patent number: 10117833
    Abstract: Provided is a method for producing a liposome having safety and stability. According to the present invention, it is possible to provide a method for producing a liposome, including a step of mixing an oil phase with at least one lipid dissolved in an organic solvent and a water phase and stirring an aqueous solution containing the lipids, and a step of evaporating the organic solvent from the aqueous solution containing the liposomes obtained in the stirring step, in which the organic solvent is a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: November 6, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Makoto Ono, Kohei Ono, Yuuko Igarasi
  • Patent number: 10117834
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 6, 2018
    Assignee: BIOGEN CHESAPEAKE LLC
    Inventor: Sven Jacobson
  • Patent number: 10117835
    Abstract: A nozzle includes a nozzle body having a fluid passageway to which extension tubes are communicated. Each extension tube includes an end having an outlet port. The outlet ports are spaced from each other. An apparatus includes the nozzle, a fluid tank into which the extension tubes extends, a fluid shear device mounted in the fluid tank, and a temperature control system in which the fluid tank is mounted. A method includes filling a water phase fluid into the fluid tank. An oil phase fluid flows out of the nozzle body via the outlet ports. The water phase fluid is disturbed and flows out of the outlet ports to form semi-products of microparticles in the fluid tank. Each semi-product has an inner layer formed by the oil phase fluid and an outer layer formed by the water phase fluid. The outer layers of the semi-products are removed to form microparticles.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: November 6, 2018
    Assignee: Metal Industries Research & Development Centre
    Inventors: Cheng-Han Hung, Zong-Hsin Liu, Ying-Chieh Lin, Ming-Fang Tsai, Hai-Ching Tsou, Ying-Cheng Lu
  • Patent number: 10117836
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 6, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Patent number: 10117837
    Abstract: Provided is a method of preparing a stimuli-responsive multifunctional nanoparticle, including in sequence the steps of: (a) conjugating covalently an active targeting moiety to a hydrophilic polymer to form a targeted polymer, (b) conjugating covalently a redox-responsive moiety to the hydrophilic polymer of the targeted polymer to form a targeted redox-responsive polymer, (c) conjugating covalently a pH-responsive moiety of a drug complex to the redox-responsive moiety of the targeted redox-responsive polymer to form a targeted stimuli-responsive polymer-drug conjugate, wherein the drug complex includes a hydrophobic drug covalently linked to the pH-responsive moiety, and (d) adding the targeted stimuli-responsive polymer-drug conjugate and optionally an imaging agent into an aqueous liquid to allow self-assembly into a stimuli-responsive multifunctional nanoparticle, wherein the hydrophobic drug of the stimuli-responsive multifunctional nanoparticle forms a hydrophobic core, and the imaging agent is incorp
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 6, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Chun-Jui Lin, Tzu-Wei Wang
  • Patent number: 10117838
    Abstract: Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 6, 2018
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Patrick Genty, Christophe Hermelin, Jean-Manuel Pean
  • Patent number: 10117839
    Abstract: A composition comprising hydrophobic droplets coated by a shell and dispersed in a matrix and a consumable product comprising the composition are provided. The hydrophobic droplets comprise a hydrophobic compound, the shell comprises an irreversibly denatured protein, and the matrix comprises a protein, a starch, and a polysaccharide. Also provided are methods for preparing the composition and the consumable product.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: November 6, 2018
    Assignee: Intervet Inc.
    Inventors: Mordechai Harel, Majid Keshtmand, Swetha Kambalapally, Sara Morrison-Rowe
  • Patent number: 10117840
    Abstract: This application describes a compound represented by Formula (I): (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 6, 2018
    Assignee: The Scripps Research Institute
    Inventors: Jiajia Dong, K. Barry Sharpless, Jeffery W. Kelly, Wentao Chen
  • Patent number: 10117841
    Abstract: The present invention includes novel chemical formulations having antimicrobial activity and their methods of use thereof. In some embodiments, the formulation further comprises at least one fungus.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: November 6, 2018
    Assignee: ECOPLANET ENVIRONMENTAL LLC
    Inventors: Gary A. Strobel, Bryan Blatt
  • Patent number: 10117842
    Abstract: This document provides methods and materials for reducing ischemia-reperfusion injury. For example, methods and materials for administering ABA to reduce tissue injury caused by reperfusion following ischemia are provided.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: November 6, 2018
    Assignee: The University of Pécs (Pécsi Tudományegyetem)
    Inventor: Agnes Nagy
  • Patent number: 10117843
    Abstract: The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 6, 2018
    Assignee: ABBVIE INC.
    Inventors: Rajkumar Conjeevaram, Alexandru Deac, Ye Huang, Sean E. Mackey, Randy A. Menges, Jayne Zimmerman
  • Patent number: 10117844
    Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 6, 2018
    Assignees: Omthera Pharmaceuticals, Inc., Chrysalis Pharma AG
    Inventors: Timothy J. Maines, Bernardus N. Machielse, Bharat M. Mehta, Gerald L. Wisler, Michael H. Davidson, Peter Ralph Wood
  • Patent number: 10117845
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: November 6, 2018
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Patent number: 10117846
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Patent number: 10117847
    Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 6, 2018
    Assignee: Ventis Pharma
    Inventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
  • Patent number: 10117848
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: November 6, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventor: Martin P. Maguire
  • Patent number: 10117849
    Abstract: The present disclosure provides a water dispersible granule formulation comprising from about 5% to about 80% (w/w) of monensin; from about 1% to about 20% (w/w) of one or more surfactants; from about 1% to about 30% (w/w) of one or more binders; from about 1% to about 90% (w/w) of one or more fillers; and water up to about 2% (w/w). The present disclosure also provides a process for the preparation of a water dispersible monensin granule formulation. The present disclosure further provides a method of administering a therapeutically effective amount of a water dispersible monensin granule formulation to an animal.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 6, 2018
    Assignee: Elanco US, Inc.
    Inventors: Kim Ewing Melville Agnew, Constantine Paul Benikos, William Austin Hewitt, Edward John Key, John Malcolm Lloyd
  • Patent number: 10117850
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 6, 2018
    Assignees: Katholieke Universiteit Leuven, K.U.Leuven R&D, reMYND
    Inventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas de la Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
  • Patent number: 10117851
    Abstract: The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 6, 2018
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Lee Alani Selvey, Marlon Carlos, Paul Maffuid, Yun Shan, William L. Betts, III, Deam Windate Given, III, Ryan M. Hart, Zezhi Jesse Shao
  • Patent number: 10117852
    Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: November 6, 2018
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Thaddeus S. Block
  • Patent number: 10117853
    Abstract: A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by general formula or a pharmacologically acceptable salt thereof: A method of treating neuropathic pain includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal. A method of treating fibromyalgia syndrome includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: November 6, 2018
    Assignee: Toray Industries, Inc.
    Inventors: Shuji Udagawa, Yasuhiro Morita, Naoki Izumimoto, Katsuhiko Iseki, Shunsuke Iwano, Tomoya Miyoshi, Yuji Osada, Tetsuro Koreeda, Masanori Murakami, Motohiro Shiraki, Kei Takahashi, Keiyu Oshida, Eriko Higashi
  • Patent number: 10117854
    Abstract: A method of treating or preventing type C Hepatic Encephalopathy in a human patient diagnosed with cirrhosis by administering a composition containing at least 200 mg biotin to the human patient daily.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: November 6, 2018
    Assignee: MEDDAY PHARMACEUTICALS
    Inventor: Frédéric Sedel
  • Patent number: 10117855
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Patent number: 10117856
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Patent number: 10117857
    Abstract: An external medicine for diffuse plexiform neurofibromas is provided. The external medicine for diffuse plexiform neurofibromas in accordance with an embodiment of the present invention contains, as an active ingredient, at least one selected from the group consisting of sirolimus and sirolimus derivatives.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: November 6, 2018
    Assignee: Osaka University
    Inventors: Mari Kaneda, Ichiro Katayama
  • Patent number: 10117858
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: November 6, 2018
    Assignee: Novartis AG
    Inventors: Urs Baettig, Kamlesh Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark LeGrand, Katrin Spiegel
  • Patent number: 10117859
    Abstract: Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: November 6, 2018
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Hong Dixon, Larry A. Cabell, Joseph A. McDonough
  • Patent number: 10117860
    Abstract: Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: November 6, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Carmelida Capaldi, Wesley Blackaby, Ian Linney, Hervé Van De Poël, Charles Baker-Glenn, Naimisha Trivedi
  • Patent number: 10117861
    Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: November 6, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
  • Patent number: 10117862
    Abstract: A remifentanil injection solution formulation contains remifentanil and or physiologically acceptable salts thereof, water, and a stabilizer, the remifentanil injection solution formulation contains said water at a rate of 0.007 to 0.025 mL per 1 mg of said remifentanil.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: November 6, 2018
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Aiko Horiuchi, Shigeru Suzuki
  • Patent number: 10117863
    Abstract: Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction utilize L-arginine or equivalents and/or derivatives thereof, and an agent that enhances the activity of the L-arginine or equivalent thereof. These enhancing agents include niacin and/or nicotinamide. Niacin and/or nicotinamide, in combination with L-arginine or its equivalent allow a desired amount of nitric oxide to be delivered or generated at the female genitals in order to increase vasodilation and blood flow to the area to enhance sexual arousal and/or pleasure and to treat sexual dysfunction.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 6, 2018
    Assignee: Life Science Enhancement Corporation
    Inventors: Guy M. Stofman, Michael J. Pelekanos
  • Patent number: 10117864
    Abstract: The present application relates to novel substituted N-bicyclo-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: November 6, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Beck, Tobias Thaler, Raimund Kast, Mark Meininghaus, Carsten Terjung, Uwe Muenster, Britta Olenik
  • Patent number: 10117865
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: November 6, 2018
    Assignee: ChemoCentryx, Inc.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jaroslaw Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Patent number: 10117866
    Abstract: Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: November 6, 2018
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Zhigang He, Kevin Park, Kai Liu, Yang Hu
  • Patent number: 10117867
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: November 6, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • Patent number: 10117868
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject subtherapeutic amounts of two or more agents that inhibit and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and/or activates Gi-protein coupled receptors, which is induced or triggered by light induced all-trans-retinal generation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Case Western Reserve University
    Inventors: Krzysztof Palczewski, Yu Chen, Akiko Maeda
  • Patent number: 10117869
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 6, 2018
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • Patent number: 10117870
    Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 6, 2018
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Charles Tokunbo Adesuyi, Bruce Hamilton Lithgow, Olivier Lambert, Lovelace Holman
  • Patent number: 10117871
    Abstract: Various embodiments described herein are directed to compounds of formula (I), (II), (III) or (IV) for use as potent inhibitors of HIV integrase and for treatment of patients afflicted with AIDS. A major challenge of human immunodeficiency virus (HIV) chemotherapy continues to be the inevitable selection of resistance by the virus towards known drug regimens. Treating resistant HIV strains calls for novel antivirals with unique structural cores. Some embodiments are directed to compounds featuring a 3-hydroxypyrimidine-2,4-dione-5-carboxamide core that consistently confers low nanomolar potencies against HIV-1 in cell culture. Biochemical testing and molecular modeling results corroborate an antiviral mechanism of action of inhibiting integrase strand transfer (INST). Preliminary testing against raltegravir-resistant HIVs showed marginal cross resistance, suggesting that the chemotypes of the various embodiments described herein could fit an inhibitory profile of second generation INSTIs.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 6, 2018
    Assignee: Regents of the University of Minnesota
    Inventor: Zhengqiang Wang
  • Patent number: 10117872
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 6, 2018
    Assignees: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto Ballestrero, Irene Caffa, Valter Longo, Alessio Nencioni, Patrizio Odetti, Franco Patrone
  • Patent number: 10117873
    Abstract: Compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 6, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Keith Biggadike, Diane Mary Coe, Xiao Qing Lewell, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
  • Patent number: 10117874
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being radium 223, particularly a pharmaceutically acceptable salt of radium-223. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of breast and prostate cancer as well as their bone metatases.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: November 6, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventor: Ningshu Liu
  • Patent number: 10117875
    Abstract: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: November 6, 2018
    Assignee: JANUS BIOTHERAPEUTICS, INC.
    Inventors: Grayson B. Lipford, Charles M. Zepp
  • Patent number: 10117876
    Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 6, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Zaima, Kazuo Kazama, Shuntaro Arase, Kentaro Nagane, Kanta Horie, Yosuke Ueki
  • Patent number: 10117877
    Abstract: Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 6, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Neil J. Poloso, Jenny Wang, David F. Woodward, Robert M. Burk
  • Patent number: 10117878
    Abstract: An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I: where Q, Q?, R1, R2, and n are defined herein, or with a stereoisomer, solvate, or pharmaceutically acceptable salt of such compound.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: November 6, 2018
    Assignee: Board of Regents, University of Texas System
    Inventors: David J. Mangelsdorf, Richard J. Auchus, Daniel L. Motola, Carolyn L. Cummins, Kamalesh K. Sharma